Read + Share
Chihara Y, Takeda T, Goto Y, Nakamura Y, et al. A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR
Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study. Oncologist 2022;27:903-e834.
PMID: 36181763
|
 |
|
Chihara Y, Takeda T, Goto Y, Nakamura Y, et al. A Phase II Trial on Osimertinib as a First-Line Treatment for EGFR
Mutation-Positive Advanced NSCLC in Elderly Patients: The SPIRAL-0 Study. Oncologist 2022;27:903-e834.
PMID: 36181763
|
|
|
|